Kanabo Group (STU:3WD) Notes Receivable: €0.00 Mil (As of Jun. 2024)


What is Kanabo Group Notes Receivable?

Kanabo Group STU:3WD Notes Receivable is €0.00 Mil as of Jun. 2024.

Kanabo Group's Notes Receivable for the quarter that ended in Jun. 2024 was €0.00 Mil.

Kanabo Group Notes Receivable Historical Data

* Premium members only.

The historical data trend for Kanabo Group's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kanabo Group Notes Receivable Chart

Kanabo Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Kanabo Group Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kanabo Group Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Kanabo Group (STU:3WD) has a Notes Receivable of €0.00 Mil as of Jun. 2024. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Kanabo Group and its competitors.
Is Kanabo Group's Notes Receivable too high?
Kanabo Group's current Notes Receivable is €0.00 Mil.
How does Kanabo Group's Notes Receivable compare to HCA and THC?
Kanabo Group's Notes Receivable of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Healthcare Providers & Services company?
A good Notes Receivable depends on the Healthcare Providers & Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Kanabo Group and its competitors. Kanabo Group's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kanabo Group stock overvalued right now?
Kanabo Group (STU:3WD) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Kanabo Group (STU:3WD), the current Notes Receivable is €0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kanabo Group Business Description

Address 137-139 Brent Street, Churchill House, London, GBR, NW4 4DJ
Kanabo Group PLC is a research and development company engaged in selling a range of THC-Free retail CBD products in the markets and it is in the process of developing medical cannabis products. Its reportable segments include Primary Care and Secondary Care. The Primary Care segment, which derives key revenue, includes Tele pharma services provided by GPS and The Secondary Care segment includes the development and distribution of cannabis-derived medical and wellness products. Geographically company has a presence in the United Kingdom and Israel.